Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
- PMID: 21392724
- PMCID: PMC3070150
- DOI: 10.1016/j.jacl.2011.02.001
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
Abstract
Background: The amount of cholesterol per low-density lipoprotein (LDL) particle is variable and related in part to particle size, with smaller particles carrying less cholesterol. This variability causes concentrations of LDL cholesterol (LDL-C) and LDL particles (LDL-P) to be discordant in many individuals.
Methods: LDL-P measured by nuclear magnetic resonance spectroscopy, calculated LDL-C, and carotid intima-media thickness (IMT) were assessed at baseline in the Multi-Ethnic Study of Atherosclerosis, a community-based cohort of 6814 persons free of clinical cardiovascular disease (CVD) at entry and followed for CVD events (n = 319 during 5.5-year follow-up). Discordance, defined as values of LDL-P and LDL-C differing by ≥ 12 percentile units to give equal-sized concordant and discordant subgroups, was related to CVD events and to carotid IMT in models predicting outcomes for a 1 SD difference in LDL-C or LDL-P, adjusted for age, gender, and race.
Results: LDL-C and LDL-P were associated with incident CVD overall: hazard ratios (HR 1.20, 95% CI [CI] 1.08-1.34; and 1.32, 95% CI 1.19-1.47, respectively, but for those with discordant levels, only LDL-P was associated with incident CVD (HR 1.45, 95% CI 1.19-1.78; LDL-C HR 1.07, 95% CI 0.88-1.30). IMT also tracked with LDL-P rather than LDL-C, ie, adjusted mean IMT of 958, 932, and 917 microm in the LDL-P > LDL-C discordant, concordant, and LDL-P < LDL-C discordant subgroups, respectively, with the difference persisting after adjustment for LDL-C (P = .002) but not LDL-P (P = .60).
Conclusions: For individuals with discordant LDL-C and LDL-P levels, the LDL-attributable atherosclerotic risk is better indicated by LDL-P.
Copyright © 2011 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Figures
), concordant; n=2246 (
), LDL-P < LDL-C discordant; n=1127 (
).Comment in
-
Can conclusions that seem discordant be concordant after all?J Clin Lipidol. 2011 Jul-Aug;5(4):261-3. doi: 10.1016/j.jacl.2011.04.006. Epub 2011 May 13. J Clin Lipidol. 2011. PMID: 21784370 No abstract available.
References
-
- Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Amer J Cardiol. 2002;90(suppl):22i–29i. - PubMed
-
- Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–44. - PubMed
-
- Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witzum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512–24. - PubMed
-
- Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847–70. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 HC095167/HC/NHLBI NIH HHS/United States
- N01HC95169/HL/NHLBI NIH HHS/United States
- N01 HC095161/HC/NHLBI NIH HHS/United States
- N01 HC095164/HC/NHLBI NIH HHS/United States
- N01-HC-95169/HC/NHLBI NIH HHS/United States
- N01HC95159/HL/NHLBI NIH HHS/United States
- N01 HC095169/HC/NHLBI NIH HHS/United States
- N01 HC095165/HC/NHLBI NIH HHS/United States
- N01 HC095168/HC/NHLBI NIH HHS/United States
- N01 HC095163/HC/NHLBI NIH HHS/United States
- N01 HC095162/HC/NHLBI NIH HHS/United States
- N01 HC095159/HC/NHLBI NIH HHS/United States
- N01-HC-95159/HC/NHLBI NIH HHS/United States
- UL1 RR025741/RR/NCRR NIH HHS/United States
- N01 HC095166/HC/NHLBI NIH HHS/United States
- N01 HC095160/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
